University of Toronto, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, Canada.
H. Lundbeck A/S, Valby, Denmark.
J Affect Disord. 2024 Oct 15;363:430-435. doi: 10.1016/j.jad.2024.07.070. Epub 2024 Jul 18.
It is previously reported that the Montgomery-Åsberg Depression Rating Scale (MADRS) anhedonia factor score is correlated with scales assessing function in patients with major depressive disorder (MDD).
This was an analysis of a database including 5 long-term, extension studies of prior controlled trials, which evaluated the effects of open-label, maintenance treatment with vortioxetine (5-20 mg/day over 1-year) in adults with MDD. We assessed the association of changes in MADRS anhedonia factor scores with changes in the Clinical Global Impression of Severity (CGI-S), Sheehan Disability scale (SDS), and the SF-36. A minimal clinically important change (MCIC) for MADRS anhedonia factor scores was determined using the CGI-S as anchor.
In patients who had completed the prior controlled studies, MADRS anhedonia factor scores continued to improve over 1-year of maintenance treatment (mean ± SE change from baseline of -6.2 ± 0.2 at Month 12). Change in MADRS anhedonia factors score correlated with change in CGI-S (Week 4, r = 0.71), SDS (Week 24 r = 0.60) and SF-36 domains (Week 24 r = -0.19 to -0.61) scores. Using a 1 level improvement on CGI-S as anchor, the MCIC for MADRS anhedonia factor scores versus baseline were - 4.6 at Week 4, -5.5 at Week 24, and - 5.3 at Week 52.
Neither the MADRS scale, nor the primary studies, were specifically designed to assess anhedonia.
These open-label data suggest that patients treated with vortioxetine continued to show clinically relevant improvements in their anhedonia over 1-year of maintenance therapy. Improvements in anhedonia correlated with improvements in measures of functioning and quality of life.
先前有报道称，蒙哥马利-阿斯伯格抑郁评定量表（MADRS）的快感缺失因子评分与评估重度抑郁症（MDD）患者功能的量表相关。
这是对包括五项先前对照试验的长期扩展研究数据库的分析，该分析评估了在 MDD 成人中，采用维拉唑汀（5-20mg/天，为期 1 年）进行开放标签、维持治疗的效果。我们评估了 MADRS 快感缺失因子评分的变化与临床总体印象严重程度（CGI-S）、Sheehan 残疾量表（SDS）和 SF-36 评分变化之间的相关性。使用 CGI-S 作为锚定物，确定 MADRS 快感缺失因子评分的最小临床重要变化（MCIC）。
在完成先前对照研究的患者中，MADRS 快感缺失因子评分在 1 年的维持治疗中持续改善（从基线到第 12 个月的平均±SE 变化为-6.2±0.2）。MADRS 快感缺失因子评分的变化与 CGI-S（第 4 周，r=0.71）、SDS（第 24 周，r=0.60）和 SF-36 各领域评分（第 24 周 r=-0.19 至-0.61）的变化相关。使用 CGI-S 改善 1 级作为锚定物，与基线相比，MADRS 快感缺失因子评分的 MCIC 在第 4 周为-4.6，第 24 周为-5.5，第 52 周为-5.3。
无论是 MADRS 量表还是主要研究，都没有专门设计用于评估快感缺失。
这些开放标签数据表明，接受维拉唑汀治疗的患者在 1 年的维持治疗中，快感缺失持续出现有临床意义的改善。快感缺失的改善与功能和生活质量测量的改善相关。
